Calcitonin Gene Therapeutic Pipeline Market Review, H2 2016

PUNE, INDIA, September 13, 2016 /EINPresswire.com/ -- The report provides comprehensive information on the Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics development and features dormant and discontinued projects.

Complete Report@ https://www.wiseguyreports.com/reports/636735-calcitonin-gene-related-peptide-review-h2-2016

Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
- The report provides a snapshot of the global therapeutic landscape for Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL)
- The report reviews Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics and enlists all their major and minor projects
- The report assesses Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) targeted therapeutics

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Get Sample Report @ https://www.wiseguyreports.com/sample-request/636735-calcitonin-gene-related-peptide-review-h2-2016

Table of Content

Bristol-Myers Squibb Company 24
Eli Lilly and Company 25
Merck & Co., Inc. 26
Teva Pharmaceutical Industries Ltd. 27
Vertex Pharmaceuticals Incorporated 28
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) - Drug Profiles 29
AA-71 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
AFAP-3 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
AGN-241689 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31

Have any query@ https://www.wiseguyreports.com/enquiry/636735-calcitonin-gene-related-peptide-review-h2-2016

erenumab - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
MK-8031 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
MK-8825 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Small Molecule to Antagonize CALCRL for Migraine - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Small Molecule to Antagonize CGRP Receptor for Migraine - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Small Molecule to Inhibit CGRP for Migraine - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Small Molecules to Agonize CLR and RAMP Receptors for Pre-Eclampsia - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Small Molecules to Antagonize Calcitonin Gene-Related Peptide for Migraine - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
ubrogepant - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=636735
Continued…

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.